unlike its competitor Austedo. Additionally, Ingrezza is not contraindicated in patients with hepatic impairments or those taking certain medications, which could further support its adoption.

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...